Ketamine is an NMDA receptor antagonist with a variety of uses, ranging from recreational drug to pediatric anesthetic and chronic pain reliever. Despite its value in the clinical setting, little is known about the immediate and long-lasting effects of repeated ketamine treatment. We assessed the effects of chronic administration of a subanesthetic dose of ketamine on contextual fear conditioning, detection of pitch deviants and auditory gating. After four, but not two, weeks of daily ketamine injections, mice exhibited decreased freezing in the fear conditioning paradigm. Gating of the P80 component of auditory evoked potentials was also significantly altered by treatment condition, as ketamine caused a significant decrease in S1 amplitude. Additionally, P20 latency was significantly increased as a result of ketamine treatment. Though no interactions were found involving test week, stimulus and treatment condition, these results suggest that repeated ketamine administration impairs fear memory and has lasting effects on encoding of sensory stimuli.
Introduction
The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is a pediatric and veterinary anesthetic whose recreational use in the United States has escalated dramatically since the 1990s (DAWN, 2003) . Though ketamine-naïve, non-drug abusers enjoy the effects of the drug at a low dose (Morgan et al., 2004a,b) , ketamine has repeatedly been shown to elicit and exacerbate psychotic symptoms (Krystal et al., 1994; Malhotra et al., 1997; Newcomer et al., 1999; Morgan et al., 2004a,b) . These symptoms, which include auditory hallucinations, blunted affect and withdrawal, are all common to patients with schizophrenia. Therefore, studies verifying the psychotic effects of ketamine not only lend support to the NMDA hypofunction model of schizophrenia but also confirm its ability to replicate behavioral analogues of the disease in non-human studies (Lindsley et al., 2006; Javitt, 2007) .
The induction of schizophrenia-related behaviors upon treatment with acute ketamine has been demonstrated in a wide range of rodent studies. In such animals acute ketamine has been shown to disrupt fear conditioning, mismatch negativity (MMN) and auditory gating, which all serve as endophenotypes for schizophrenia (Brown et al., 2000; Javitt, 2000; Michie, 2001; Winterer et al., 2001; Ong et al., 2005; Maxwell et al., 2006; Pietersen et al., 2007; Ehrlichman et al., 2008) . Episodic memory impairments are the most severe cognitive dysfunctions associated with schizophrenia (Heinrichs and Zakzanis, 1998). For this reason, the fear conditioning paradigm, in which an initially neutral (conditioned) stimulus is paired with an aversive (unconditioned) stimulus, is often used to assess memory in animal models of the disease.
In the MMN paradigm, a set of repeated stimuli is followed by a deviant, such as a tone of differing frequency. People with schizophrenia have a decreased ability to detect auditory deviants as measured by changes to the N100 and mismatch negativity (MMN) of their auditory evoked potentials (AEPs) (Javitt, 2000; Michie, 2001; Davalos et al., 2003) . The N100 is the negative-most deflection in the human AEP, a modality of event-related potentials (ERPs) occurring approximately 100 milliseconds (ms) post-stimulus whose mouse analog is termed the N40 (Yingling and Nethercut, 1983; Covington and Polich, 1996; Shelley et al., 1999) . The MMN generally occurs immediately following the N100 and is manifest as an amplified negative deflection to deviant stimuli (May et al., 1999; Haenschel et al., 2005) . Gating refers to a reduction in the second of two successive stimuli. Patients with schizophrenia also exhibit impaired 
